Powder: -20°C for 3 years | In solvent: -80°C for 1 year
OTS193320, an imidazopyridine compound, acts as an inhibitor of SUV39H2 methyltransferase activity. It effectively reduces global histone H3 lysine 9 tri-methylation levels in breast cancer cells, promoting apoptotic cell death. When combined with Doxorubicin (DOX; HY-15142A), OTS193320 enhances the reduction of γ-H2AX levels and decreases cancer cell viability more significantly than when either agent is used alone.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 275,500 |
50 mg | 約6-8 週間 | ¥ 358,000 |
100 mg | 約6-8 週間 | ¥ 544,000 |
説明 | OTS193320, an imidazopyridine compound, acts as an inhibitor of SUV39H2 methyltransferase activity. It effectively reduces global histone H3 lysine 9 tri-methylation levels in breast cancer cells, promoting apoptotic cell death. When combined with Doxorubicin (DOX; HY-15142A), OTS193320 enhances the reduction of γ-H2AX levels and decreases cancer cell viability more significantly than when either agent is used alone. |
分子量 | 536.02 |
分子式 | C28H30ClN5O4 |
CAS No. | 2093401-33-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
OTS193320 2093401-33-1 Inhibitor inhibitor inhibit